Search

CN-121971613-A - Application of ANKRD13A as target in preparation of anti-enteritis drugs

CN121971613ACN 121971613 ACN121971613 ACN 121971613ACN-121971613-A

Abstract

The application provides application of ANKRD13A as a target spot in preparing anti-enteritis drugs, relates to the technical field of biomedicine, and has the technical key points that the application of ANKRD13A as a target spot in preparing anti-enteritis drugs, wherein a protein sequence of the protein sequence is shown as SEQ ID NO. 01. According to the application, through analyzing a GEO public data set, the mRNA expression level of ANKRD13A in intestinal mucosa of adult and pediatric Ulcerative Colitis (UC) patients is obviously lower than that of a healthy control group, a Ankrd a gene knockout mouse model is constructed, the gene deletion is found to not influence colon development and functions in a steady state, after DSS induction of acute colitis, the death rate of the knockout mouse is increased, the susceptibility of the colitis is increased, the colon is shortened, the intestinal epithelial damage is aggravated, and the immune cell infiltration is increased. The application defines the key regulation and control function of ANKRD13A in ulcerative colitis, provides experimental basis for developing anti-enteritis drug targets and diagnostic markers, and can be used for preventing and treating enteritis.

Inventors

  • FAN YIHUI
  • ZHENG WEN
  • MAO RENFANG

Assignees

  • 南通大学

Dates

Publication Date
20260505
Application Date
20260116

Claims (9)

  1. The application of ANKRD13A as a target in preparing anti-enteritis medicaments is characterized in that the ANKRD13A protein sequence is shown as SEQ ID NO. 01.
  2. 2. The use of ANKRD13A as target spot in preparing anti-enteritis medicament as claimed in claim 1, wherein the anti-enteritis medicament is used for preventing enteritis or treating enteritis.
  3. 3. The use of ANKRD13A as target in the manufacture of a medicament against enteritis comprising ulcerative colitis according to claim 1.
  4. 4. An anti-enteritis medicament for preventing and treating enteritis is characterized in that the medicament comprises molecules for promoting ANKRD13A expression.
  5. 5. The anti-enteritis drug of claim 4, wherein the molecule comprises one of recombinant ANKRD13A protein, an ANKRD13A overexpression vector, a small molecule compound targeted to activate ANKRD13A gene transcription, a stabilizer to inhibit ANKRD13A degradation, and a microRNA inhibitor targeted to regulate ANKRD13A expression.
  6. 6. The enteritis drug of claim 5, wherein the ANKRD13A overexpression vector is one of an adenovirus vector, a lentiviral vector and a plasmid vector.
  7. 7. The anti-enteritis drug of claim 5, further comprising a pharmaceutically acceptable adjuvant.
  8. The application of ANKRD13A as a target in preparing a enteritis diagnosis product is characterized in that the product comprises a detection kit or a detection reagent.
  9. 9. The use of ANKRD13A as target in the preparation of a diagnostic product for enteritis according to claim 8, wherein said product further comprises a probe specifically binding to ANKRD13A, a specific primer for ANKRD13A mRNA, an antibody specific for ANKRD13A protein, a positive control, a negative control, a detection buffer, enzymes, chromogenic reagents or fluorescent markers.

Description

Application of ANKRD13A as target in preparation of anti-enteritis drugs Technical Field The application relates to the technical field of biomedicine, in particular to application of ANKRD13A as a target spot in preparation of anti-enteritis drugs. Background Enteritis is a common digestive system disease, manifested by inflammation of the mucous membranes of the small or large intestine. Enteritis is often caused by a variety of causes, such as bacteria, viruses, fungi, parasites, and the like. The clinical manifestations are mainly abdominal pain, diarrhea, watery stool or mucopurulent bloody stool. Among these, inflammatory Bowel Diseases (IBD), including crohn's disease and ulcerative colitis, are a type of enteritis of complex etiology and high mortality, and are quite different from common enteritis. Ulcerative colitis (Ulcerative Colitis, UC) is a chronic, recurrent inflammatory disease of the intestinal tract, mainly involving the mucosal layers of the colon and rectum. Clinically, patients often present with symptoms such as abdominal pain, chronic diarrhea, rectal bleeding, and weight loss. From an epidemiological perspective, UC is no longer a "proprietary" disease in western countries, and research data has shown that this chronic disease has become a worldwide health problem, particularly in asia, latin america and some emerging industrialized countries in the middle east, where the incidence and hospitalization of UC is increasing significantly. Chronic inflammation is an important driver of cancer occurrence and progression from a pathophysiological point of view, and for ulcerative colitis patients, long-standing intestinal inflammation can significantly increase the risk of cancer. The treatment regimen for patients with ulcerative colitis is primarily tailored and adjusted according to the severity of the disease. For mild or moderate patients, conventional drugs such as aminosalicylic acid (5-ASA), corticosteroids may be used, however, these drugs may have certain side effects and adverse reactions. Severe patient maintenance therapy relies on more complex classes of drugs, including immunosuppressives (e.g., thiopurines), biologies (e.g., anti-TNF antibodies, anti-integrin drugs, anti-IL-12 and anti-IL-23 monoclonal antibodies), and small molecule drugs (e.g., janus kinase inhibitors and sphingosine-1 receptor modulators), although a variety of drugs and therapies have been developed in recent years, clinical efficacy has remained elusive. Some patients do not respond to existing treatment regimens or develop drug resistance, suggesting that our understanding of the pathogenesis of UC is not yet adequate. Endoscopy is widely regarded as the most effective means of diagnosing ulcerative colitis, and is not widely accepted by patients due to its expensive, invasive procedure. Other biochemical indexes cannot be used as gold standard for diagnosis due to limitations in sensitivity and specificity. In view of the above, the treatment and diagnosis of ulcerative colitis still face significant challenges, so we have an urgent need to explore the pathogenesis of UC in depth, search for more potent effector molecules, and convert them into clinically useful therapeutic targets. Meanwhile, how to develop an accurate biomarker detection method to realize early diagnosis and dynamic detection is still the key direction of current research. Disclosure of Invention The application aims to solve the technical problem that biomarkers aiming at UC are lacking in the prior art. The application is realized by the following technical scheme: the application of ANKRD13A as a target in preparing anti-enteritis medicines is provided, wherein the ANKRD13A protein sequence is shown as SEQ ID NO. 01. Preferably, the anti-enteritis medicament is used for preventing enteritis or treating enteritis. Preferably, the enteritis comprises ulcerative colitis. The application also provides an anti-enteritis medicament for preventing and treating enteritis, which comprises molecules for promoting ANKRD13A expression. Preferably, the molecule comprises one of a recombinant ANKRD13A protein, an ANKRD13A overexpression vector, a small molecule compound targeted to activate transcription of the ANKRD13A gene, a stabilizer to inhibit degradation of ANKRD13A, and a microRNA inhibitor targeted to regulate expression of ANKRD 13A. Preferably, the ANKRD13A overexpression vector is one of an adenovirus vector, a lentiviral vector and a plasmid vector. Preferably, the medicament further comprises a pharmaceutically acceptable adjuvant. The application also provides application of ANKRD13A as a target in preparing enteritis diagnostic products, wherein the products comprise detection kits or detection reagents. Preferably, the product further comprises a probe which specifically binds to ANKRD13A, a specific primer aiming at ANKRD13A mRNA, an ANKRD13A protein specific antibody, a positive control, a negative control, a detection buf